Table 4.
Treatment and outcomes in MIS-C
| Parameters | Grimaud et al. | Verdoni et al. | Whittaker et al. | Feldstein et al. | Dufort et al. | Capone et al | Davies et al. |
|---|---|---|---|---|---|---|---|
| Intensive care | 100% | NA | 50% | 80% | 80% | 79% | NA |
| High flow nasal O2 | 5 | NA | NA | 26% | 16% | 52% | 17% |
| Invasive mechanical ventilation | 40 | NA | 43% | 20% | 10% | 18% | 46% |
| Vasopressor support | 95% | 20% | 47% | 48% | 62% | 76% | 83% |
| ECMO | Nil | NA | 5% | 4% | 4% | NA | 4% |
| Dialysis | Nil | NA | NA | 3% | NA | NA | 1% |
| IVIG | 100% | 100% | 71% | 77% | 70% | 100% | 76% |
| Any anticoagulation/antiplatelet | NA | 20% | NA | 47% | NA | 88% | 58% |
| Corticosteroids | 10% | 80% | 64% | 49% | 64% | 70% | 73% |
| Anti-IL-6 receptor antagonist | 5% | Nil | NA | 8% | NA | 9% | 4% |
| Anti-IL-1 receptor antagonist | 5% | Nil | 5% | 13% | NA | 12% | 10% |
| TNF alpha antagonist | Nil | Nil | 14% | Nil | NA | 3% | 9% |
| Mortality | Nil (all survived) | Nil (all survived) | 2% | 2% | 2% | Nil (all survived) | 3% |
NA—data not available